Loading chat...
NJ A4057
Bill
Status
3/11/2024
Primary Sponsor
Julio Marenco
Click for details
AI Summary
-
Requires general acute care hospitals to include testing for fentanyl, xylazine, and any drug subject to a Commissioner of Health public health overdose alert when conducting urine drug screenings to diagnose patient conditions
-
Mandates hospitals report de-identified positive test results for these substances to the Department of Health in a form prescribed by the Commissioner
-
Allows hospitals without urinalysis analyzer equipment to use fentanyl, xylazine, or other drug test strips to comply with the testing requirements
-
Preserves existing mandatory reporting requirements related to opioids, drug overdoses, and other substances required by state agencies
-
Takes effect 90 days after enactment
Legislative Description
Requires hospitals to test for fentanyl and xylazine as part of urine drug screenings.
Financial Institutions and Insurance
Last Action
Reported out of Asm. Comm. with Amendments, and Referred to Assembly Financial Institutions and Insurance Committee
5/13/2024